Late in the day on Friday, Kansas City animal health company Aratana Therapeutics announced successful results of a pivotal trial of capromorelin (AT-002), which stimulates appetite in dogs. The company's shares skyrocketed 25% to $16.74 in after-hours trading.
A litter of pigs designed to be resistant to African swine fever (ASF) were recently born at a farm outside Edinburgh, Scotland, making them among the first commercially viable genetically modified animals born in Britain.
The impact of the deadly outbreak of H5N2 avian influenza, which has sickened more than 48 million birds and forced poultry producers to cull their flocks, has trickled down to grocery stores and restaurant owners. The USDA predicts egg production will fall 5% this year to 6.9 billion dozen, and that shortage is translating to higher prices.
POPULAR COMMENT THREADS
Just one day after the Wall Street Journal reported that Valeant had made a buyout bid for Zoetis, sending shares of the animal health giant up 11% to an all-time high of $55.48, investors started doubting the deal would happen. As of Monday's stock market opening, no details about the acquisition attempt had been released, and shares opened trading at just over $48--erasing all the gains that had come from the rumor.
The U.S. Department of Agriculture has amended its rules to allow veterinarians to make vaccines in their offices for individual clients, so long as compounds aren't contracted out to unlicensed manufacturers.
A week after rumors of a Valeant takeover sent shares of Zoetis flying 11% to an all-time high of $55.48--and then crashing right back down when no bid emerged--investors have been given another tantalizing scenario to ponder about the much-discussed animal health giant. On June 29, Canaccord Genuity analyst Mark Massaro published a report suggesting Zoetis might have both the resources and the desire to acquire veterinary diagnostics maker IDEXX.
Just two months after hiring Bank of America to explore a selloff of its medical-equipment unit, distributor Patterson Companies has found a buyer. The Minnesota company announced on Wednesday that it will be selling Patterson Medical to private equity firm Madison Dearborn Partners for $715 million. The deal is expected to close next quarter.
In late June, drug regulators from around the world gathered in Dar Es Salaam, Tanzania, to brainstorm solutions for solving a major problem in many African countries and other developing nations: a lack of access to veterinary care, and most importantly, to particular drugs and vaccines that could protect against livestock losses.
A compound called resiniferatoxin, now in a Phase I/II study at the National Institutes of Health to treat intractable pain in people with end-stage cancer, has been shown in early trials in pet dogs to be effective in relieving pain from canine bone cancer and osteoarthritis.
From Our Sister Sites
A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.
Vertex Pharmaceuticals won the FDA's blessing to market a new combination therapy for cystic fibrosis, clearing the way for a drug key to the company's future as it moves away from antiviral treatments.